Key facts
- Notable investors include TEDCO.
- EPOCH Epigenetics has filed 1 Form D with the SEC, most recently Jun 2025 ($73K sold to 1 investors).
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for EPOCH Epigenetics
- ·The full record, as it builds
Funding rounds
No funding rounds for EPOCH Epigenetics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About EPOCH Epigenetics
Developer of molecular biology process tools designed for laboratory and biotech research purposes. The company offers DNA and RNA extraction, cloning, sequencing, and purification, incorporating optimized reagents and protocols that support throughput processing, reproducibility, and cost effectiveness, enabling research laboratories and biotechnology firms to accelerate scientific discovery and enhance clinical diagnostics.
- Sector
- Healthcare
- HQ
- Severna Park, MD, United States
- Founded
- 2023
- Ownership
- Privately Held (backing)
EPOCH Epigenetics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in EPOCH Epigenetics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on EPOCH Epigenetics in its N-PORT filings yet. We sweep new filings monthly.